🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Many talks are associating PD-L1 tumor expression with clinical outcome- yet don't tell us definition of PD-L1 positivity. Is it 50%, 5%, 1%? On tumor? On immune "hot-spots"? on APC? Hard to figure out the utility of association. #ImmunoOnc19 UW Cancer Vaccine Institute

Surely there must be more data supporting a Phase III than just these 20 patients....!!!!#ImmunoOnc19

Sounds exciting for endometrial cancer! #ImmunoOnc19

Dr. Palucka highlights the issues associated with mutated antigen vaccines; the mutations have to be presented enodogenously in the patients MHC. Most are not. #Immunotherapy #immunoonc19 UW Cancer Vaccine Institute

Dendritic cells are the most important antigen presenting cells for stimulating T-cell responses to cancer. Nobel Prize winning tumor immunologist Dr. Ralph Steinman was honored for his work in this area. #ImmunoOnc19

Dr. Palucka highlights the importance of DC in mediating response to ICI. Recent Immunity paper implicated IFN-g and IL-12 in T cell DC cross-talk. bit.ly/2tHGyxp #ImmunoOnc19 UW Cancer Vaccine Institute

Dr. Kandalaft points out that there are many types of antigens that can be used for vaccination, neo antigens of all types- not just point mutations. Target epigenetic changes, phospho Ag...etc. #ImmunoOnc19 UW Cancer Vaccine Institute

VERY IMPORTANT COMMENT!!! #ImmunoOnc19 UW Cancer Vaccine Institute

Patient page on #CIPN (Chemo Induced Peripheral Neuropathy), in JAMA Oncology w/ Tim Brown, MD MSCE Ramy Sedhom, MD, FASCO #QOL matters. Can be photocopied non-commercially to share with patients. jamanetwork.com/journals/jamao…

Thank you UW CVI #ImmunoOnc19 UW Cancer Vaccine Institute

I'm a fan of testing early. Immune therapy more be more effective with less bulky disease.

Regulatory roles of IL-10–producing human follicular T cells jem.rupress.org/content/early/…

Pembrolizumab After Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer ja.ma/2O5xGif New at @JAMA Onc-ablation of oligometastatic NSCLC followed by immune checkpoint: OS at 12 mo-90%. Novel and promising application of immune checkpoint inhibition.

Thanks for my nicest colleagues! I am the best, because all of you! UW Cancer Vaccine Institute

Laura is an amazing scientist!

5 immune response markers might predict #COVID19 patient outcomes & possibly become useful in candidate vaccine assessment, according to Immunity Cell study Ragon Institute & UW Medicine headed by Galit Alter & Helen Chu bit.ly/2DrtULn

In the wake of #ADAURA trial, what will your practice be for molecular testing in patients with resected stage IB-IIIA NSCLC? Please amplify as needed in the comments. #LCSM

👨‍⚕️👩‍⚕️ Drs. Sasha Stanton (Sasha Stanton, MD PhD), Nora Disis (Mary L. (Nora) Disis), and fellow UW Cancer Vaccine Institute researchers found that candidate targets recovered from mouse #mammary tumor models are also immunogenic in human #BreastCancer. 📚 Abstact: go.nature.com/3y780Vb

We’re excited to share a new paper by CVI’s Dr. John Liao on a clinical trial for combination Pembrolizumab and low dose carboplatin in women with recurrent, platinum resistant ovarian cancer. Read more uwcvi.org/post/new-cvi-p… #ovariancancerawarenessmonth #gyncsm #immunotherapy

x.com/UWCancerVaccin…